5Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007, 7(57) :43 -46.
6Ian F. Tannock, Ronald de Wit. , William R. Berry, et al. Do- cetaxel plus Prednisone or Mitoxantrone plus Prednisone for Ad- vanced Prostate Cancer. N Engl J Med. 2004, 351 (15) :1502 - 1512.
7Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and Es- tramustine Compared with Mitoxantrone and Prednisone for Ad- vanced Refractory Prostate Cancer. N Engl J Med. 2004, 351 ( 15 ) :1513 - 1520.
8Guy J. Berchem, Manon Bosseler, LaVencia Y. Sugars, et al. Androgens Induce Resistance to bcl - 2 - mediated Apoptosis in LNCaP Prostate Cancer Cells. Cancer Research. 1995, 55 (4) : 735 - 738.
9Shi XB, Ma AH, Tepper CG, et al. Molecular alterations associat- ed with LNCaP cell progression to androgen independence. Pros- tate. 2004, 60(3) :257 -271.
10Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to ag- onist of the androgen receptor blocker bicalutamide is associated with prostate tumor progression in a new model system. British Journal of Cancer. 1999, 81 (2) : 242 -251.
